FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$124M
This Quarter Return
-22.89%
1 Year Return
-24.36%
3 Year Return
+1.86%
5 Year Return
+16.17%
10 Year Return
–
AUM
$218M
AUM Growth
+$218M
(-29%)
Cap. Flow
-$14.2M
Cap. Flow
% of AUM
-6.5%
Top 10 Holdings %
Top 10 Hldgs %
82.07%
Holding
26
New
5
Increased
5
Reduced
6
Closed
8
Top Buys
| 1 |
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
|
$10.5M |
| 2 |
AERI
Aerie Pharmaceuticals, Inc.
AERI
|
$9.45M |
| 3 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
$4.88M |
| 4 |
CBAY
Cymabay Therapeutics
CBAY
|
$4.78M |
| 5 |
SI-BONE Inc
SIBN
|
$4.3M |
Top Sells
| 1 |
ALDR
Alder Biopharmaceuticals, Inc.
ALDR
|
$16.7M |
| 2 |
Omeros
OMER
|
$8.69M |
| 3 |
Rhythm Pharmaceuticals
RYTM
|
$7.98M |
| 4 |
Xenon Pharmaceuticals
XENE
|
$5.09M |
| 5 |
Arbutus Biopharma
ABUS
|
$4.19M |
Sector Composition
| 1 | Healthcare | 85.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BHVN
1
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $31.7M | 14.53% | 855,900 +4,700 | +0.6% | +$174K |
|
2
Insmed
INSM
$28.8B
| $25.9M | 11.91% | 1,977,236 +176,649 | +10% | +$2.32M |
|
|
MYOK
3
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $23.8M | 10.91% | 486,624 -24,620 | -5% | -$1.2M |
|
|
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
| $20.7M | 9.5% | 2,631,258 +607,889 | +30% | +$4.78M |
|
|
IMMU
5
DELISTED
Immunomedics Inc
IMMU
| $17.2M | 7.9% | 1,205,363 -26,180 | -2% | -$374K |
|
6
Ascendis Pharma
ASND
$11.8B
| $15.4M | 7.06% | 245,424 | – | – |
|
7
Replimune Group
REPL
$422M
| $12.3M | 5.64% | 1,229,656 | – | – |
|
|
8
Rhythm Pharmaceuticals
RYTM
$6.85B
| $10.8M | 4.94% | 400,000 -296,903 | -43% | -$7.98M |
|
|
OPTN
9
DELISTED
OptiNose
OPTN
| $10.6M | 4.86% | 1,708,545 +250,000 | +17% | +$1.55M |
|
|
ORTX
10
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $10.5M | 4.83% | +668,361 | New | +$10.5M |
|
|
AERI
11
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $9.45M | 4.34% | +261,823 | New | +$9.45M |
|
|
12
Arbutus Biopharma
ABUS
$711M
| $6.06M | 2.78% | 1,582,275 -1,094,550 | -41% | -$4.19M |
|
|
EIDX
13
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $5.94M | 2.73% | 431,781 -93,219 | -18% | -$1.28M |
|
14
Aclaris Therapeutics
ACRS
$209M
| $5.53M | 2.54% | 748,132 +218,581 | +41% | +$1.62M |
|
|
PTLA
15
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $4.88M | 2.24% | +250,000 | New | +$4.88M |
|
|
16
SI-BONE Inc
SIBN
$719M
| $4.3M | 1.97% | +205,621 | New | +$4.3M |
|
17
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $1.8M | 0.82% | 63,922 -30,555 | -32% | -$858K |
|
18
Cytokinetics
CYTK
$4.23B
| $1.11M | 0.51% | +175,148 | New | +$1.11M |
|
19
Crinetics Pharmaceuticals
CRNX
$2.92B
| – | – | -49,600 | Closed | -$1.42M |
|
|
20
Omeros
OMER
$283M
| – | – | -356,000 | Closed | -$8.69M |
|
21
uniQure
QURE
$896M
| – | – | -10,650 | Closed | -$388K |
|
22
Arcus Biosciences
RCUS
$1.13B
| – | – | -295,000 | Closed | -$4.11M |
|
|
VRNA
23
Verona Pharma
VRNA
$9.16B
| – | – | -8,302 | Closed | -$104K |
|
|
24
Xenon Pharmaceuticals
XENE
$2.98B
| – | – | -385,714 | Closed | -$5.09M |
|
|
GRTS
25
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| – | – | -175,000 | Closed | -$2.49M |
|